<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175018</url>
  </required_header>
  <id_info>
    <org_study_id>AHA 10SDG3030051</org_study_id>
    <nct_id>NCT01175018</nct_id>
  </id_info>
  <brief_title>Anakinra to Prevent Adverse Post-infarction Remodeling (2)</brief_title>
  <acronym>VCU-ART2</acronym>
  <official_title>Anakinra to Prevent Adverse Post-infarction Remodeling (2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myocardial infarction (AMI) remains a major cause of morbidity and mortality. Many
      patients die early during the course, and those who survive are at risk for dying late from
      adverse cardiac remodeling and heart failure.

      The initial ischemic damage to the myocardium initiates an intense inflammatory response in
      promoting further cardiac dysfunction and heart failure. The investigators propose that an
      antiinflammatory strategy based on blockade of Interleukin-1 will quench the inflammatory
      response and lead to a more favorable cardiac remodeling process.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute myocardial infarction (AMI) remains a major cause of morbidity and mortality. Many
      patients die early during the course, and those who survive are at risk for dying late from
      adverse cardiac remodeling and heart failure.

      The initial ischemic damage to the myocardium initiates an intense inflammatory response in
      promoting further cardiac dysfunction and heart failure. Interleukin-1 (IL-1) is the
      prototypical inflammatory cytokine involved in the tissue response to injury. In the
      experimental model of large anterior wall AMI in the mouse, IL-1 blockade using anakinra, a
      recombinant human IL-1 receptor antagonist ameliorates cardiac remodeling and improves
      survival following AMI. Although the mouse AMI model is helpful in understanding the events
      leading to adverse post-infarction cardiac remodeling and heart failure, the exact role of
      IL-1 in patients with AMI has not been completely characterized. The investigators propose to
      address this question by studying patients presenting with ST-segment elevation AMI (STEMI).
      Such patients are at high risk for in-hospital and long-term mortality and display several
      markers of inflammation. The investigators hypothesize that IL-1 blockade in patients STEMI
      with will limit the acute inflammatory response and prevent adverse cardiac remodeling, heart
      failure, and related morbidity.

      The investigators hypothesize that treatment with anakinra will lead to more favorable
      cardiac remodeling. Left ventricular end-systolic volume index (LVESVi) is the preferred
      clinical marker of adverse cardiac remodeling and a strong predictor of heart failure-related
      mortality in patients with STEMI, and will be used as primary endpoint of the study. The
      investigators propose that anakinra will reduce the change in LVESVi from baseline to 10-14
      weeks after STEMI, and will prevent, at least in part, other changes in cardiac function and
      exercise tolerance associated with adverse cardiac remodeling and heart failure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-systolic Volume Indices</measure>
    <time_frame>10-14 weeks minus baseline</time_frame>
    <description>Change in n left ventricular end-systolic volume indices from baseline to follow up exam at cardiac magnetic resonance imaging comparing anakinra- and placebo-treated patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-diastolic Volume Indices From Baseline to Follow up Exam at Cardiac Magnetic Resonance Imaging</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Each Group With Reverse Remodeling (Reduction in LVESVi &gt;5%)</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Difference Between the 2 Arms in the Peak Oxygen Consumption (VO2) at 10-14 Weeks</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Heart Failure</measure>
    <time_frame>10-14 weeks</time_frame>
    <description>Difference between the anakinra arm and the placebo arm in number of patients with a new diagnosis or admission to the hospital for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events in Each Group</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between the 2 Arm in the Interval Change in Right Ventricular Ejection Fraction (RVEF)</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular Ejection Fraction Values From Baseline to Follow up Exam at Cardiac Magnetic Resonance Imaging</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Difference Between the 2 Arms in the Ratio of Minute Ventilation and Carbon Dioxide Production (VE/VCO2 Slope) at 10-14 Weeks</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Each Group With Reverse Remodeling (Reduction in LVESVi &gt;10%)</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Each Group With Adverse Remodeling (LVESVi Increase &gt;5%) Based Upon Cardiac Magnetic Resonance Imaging</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Each Group With Adverse Remodeling (LVESVi Increase &gt;10%)</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Each Group With Left Ventricular Ejection Fraction Change &gt;5%</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Each Group With Left Ventricular Ejection Fraction Change &gt;10%</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths in Each Group</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events Requiring Withdrawal in Each Group</measure>
    <time_frame>10-14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra 100 mg injectable subcutaneously daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.67 ml of sodium chloride (NaCl) 0.9% solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>Anakinra 100 mg s.c. daily for 14 days</description>
    <arm_group_label>Anakinra</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with STEMI will be asked to enroll according to the following inclusion
             criteria:

               -  age &gt; 18 years,

               -  acute (&lt;12 h) onset of chest pain associated with ST segment elevation (&gt;2 mm) in
                  2 or more anatomically contiguous leads at ECG,

               -  and successful primary percutaneous coronary intervention.

        Exclusion criteria:

          -  inability to give informed consent,

          -  late presentation (&gt;12 h),

          -  unsuccessful revascularization procedure,

          -  hemodynamic instability including hypotension,

          -  prior Q-wave AMI,

          -  end-stage congestive heart failure (American Heart Association [AHA]/American College
             of Cardiology [ACC] class C-D, New York Heart Association IV), severe left ventricular
             dysfunction (EF&lt;20%),

          -  severe valvular heart disease,

          -  pregnancy, dye allergy or contraindications to cardiac angiography and/or magnetic
             resonance imaging, coagulopathy (INR&gt;1.5 or platelet count&lt;50000/mm3),

          -  recent (&lt;14 days) use of anti-inflammatory drugs (not including NSAIDs),

          -  chronic inflammatory disease (including but not limited to rheumatoid arthritis,
             systemic lupus erythematosus), and malignancy or any comorbidity limiting survival or
             conditions predicting inability to complete the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Abbate, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pauleyheart.vcu.edu</url>
    <description>VCU Pauley Heart Center</description>
  </link>
  <reference>
    <citation>Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CS, Varma A, Gelwix CC, Salloum FN, Hastillo A, Dinarello CA, Vetrovec GW; VCU-ART Investigators. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010 May 15;105(10):1371-1377.e1. doi: 10.1016/j.amjcard.2009.12.059. Epub 2010 Apr 2.</citation>
    <PMID>20451681</PMID>
  </reference>
  <results_reference>
    <citation>Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, Abouzaki NA, Rengel LR, Varma A, Gambill ML, Falcao RA, Voelkel NF, Dinarello CA, Vetrovec GW. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013 May 15;111(10):1394-400. doi: 10.1016/j.amjcard.2013.01.287. Epub 2013 Feb 27.</citation>
    <PMID>23453459</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2010</study_first_posted>
  <results_first_submitted>October 22, 2013</results_first_submitted>
  <results_first_submitted_qc>May 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2016</results_first_posted>
  <last_update_submitted>May 9, 2016</last_update_submitted>
  <last_update_submitted_qc>May 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Cardiac Remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Anakinra</title>
          <description>Anakinra 100 mg injectable subcutaneously daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>0.67 ml of sodium chloride (NaCl) 0.9% solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anakinra</title>
          <description>Anakinra 100 mg injectable subcutaneously daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>0.67 ml of NaCl 0.9% solution</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="12"/>
                    <measurement group_id="B2" value="58" spread="12"/>
                    <measurement group_id="B3" value="59" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-systolic Volume Indices</title>
        <description>Change in n left ventricular end-systolic volume indices from baseline to follow up exam at cardiac magnetic resonance imaging comparing anakinra- and placebo-treated patients.</description>
        <time_frame>10-14 weeks minus baseline</time_frame>
        <population>Applies only to subset of patients with magnetic resonance imaging (MRI) at baseline and 10-14 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-systolic Volume Indices</title>
          <description>Change in n left ventricular end-systolic volume indices from baseline to follow up exam at cardiac magnetic resonance imaging comparing anakinra- and placebo-treated patients.</description>
          <population>Applies only to subset of patients with magnetic resonance imaging (MRI) at baseline and 10-14 weeks.</population>
          <units>mL/m2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="-3" upper_limit="3"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-4.5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-diastolic Volume Indices From Baseline to Follow up Exam at Cardiac Magnetic Resonance Imaging</title>
        <time_frame>10-14 weeks</time_frame>
        <population>Applies only to subset of patients with magnetic resonance imaging (MRI) at baseline and 10-14 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily
Anakinra: Anakinra 100 mg s.c. daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution
Placebo: 0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-diastolic Volume Indices From Baseline to Follow up Exam at Cardiac Magnetic Resonance Imaging</title>
          <population>Applies only to subset of patients with magnetic resonance imaging (MRI) at baseline and 10-14 weeks.</population>
          <units>mL/m2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="-3" upper_limit="10"/>
                    <measurement group_id="O2" value="-4" lower_limit="-12" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients in Each Group With Reverse Remodeling (Reduction in LVESVi &gt;5%)</title>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients in Each Group With Reverse Remodeling (Reduction in LVESVi &gt;5%)</title>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Difference Between the 2 Arms in the Peak Oxygen Consumption (VO2) at 10-14 Weeks</title>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Median Difference Between the 2 Arms in the Peak Oxygen Consumption (VO2) at 10-14 Weeks</title>
          <units>ml*kg^-1*min^-1</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-13" upper_limit="1"/>
                    <measurement group_id="O2" value="2.5" lower_limit="-1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Heart Failure</title>
        <description>Difference between the anakinra arm and the placebo arm in number of patients with a new diagnosis or admission to the hospital for heart failure</description>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Heart Failure</title>
          <description>Difference between the anakinra arm and the placebo arm in number of patients with a new diagnosis or admission to the hospital for heart failure</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events in Each Group</title>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events in Each Group</title>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between the 2 Arm in the Interval Change in Right Ventricular Ejection Fraction (RVEF)</title>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between the 2 Arm in the Interval Change in Right Ventricular Ejection Fraction (RVEF)</title>
          <units>% (absolute change)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="-2" upper_limit="11"/>
                    <measurement group_id="O2" value="4" lower_limit="-4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular Ejection Fraction Values From Baseline to Follow up Exam at Cardiac Magnetic Resonance Imaging</title>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular Ejection Fraction Values From Baseline to Follow up Exam at Cardiac Magnetic Resonance Imaging</title>
          <units>% (absolute change)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-2" upper_limit="10"/>
                    <measurement group_id="O2" value="-2" lower_limit="-5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Difference Between the 2 Arms in the Ratio of Minute Ventilation and Carbon Dioxide Production (VE/VCO2 Slope) at 10-14 Weeks</title>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Median Difference Between the 2 Arms in the Ratio of Minute Ventilation and Carbon Dioxide Production (VE/VCO2 Slope) at 10-14 Weeks</title>
          <units>(no units; ratio of values)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-17" upper_limit="2"/>
                    <measurement group_id="O2" value="-3" lower_limit="-6" upper_limit="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients in Each Group With Reverse Remodeling (Reduction in LVESVi &gt;10%)</title>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients in Each Group With Reverse Remodeling (Reduction in LVESVi &gt;10%)</title>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients in Each Group With Adverse Remodeling (LVESVi Increase &gt;5%) Based Upon Cardiac Magnetic Resonance Imaging</title>
        <time_frame>10-14 weeks</time_frame>
        <population>Applies only to subset of patients with magnetic resonance imaging (MRI) at baseline and 10-14 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients in Each Group With Adverse Remodeling (LVESVi Increase &gt;5%) Based Upon Cardiac Magnetic Resonance Imaging</title>
          <population>Applies only to subset of patients with magnetic resonance imaging (MRI) at baseline and 10-14 weeks.</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients in Each Group With Adverse Remodeling (LVESVi Increase &gt;10%)</title>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients in Each Group With Adverse Remodeling (LVESVi Increase &gt;10%)</title>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients in Each Group With Left Ventricular Ejection Fraction Change &gt;5%</title>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients in Each Group With Left Ventricular Ejection Fraction Change &gt;5%</title>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients in Each Group With Left Ventricular Ejection Fraction Change &gt;10%</title>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients in Each Group With Left Ventricular Ejection Fraction Change &gt;10%</title>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Deaths in Each Group</title>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths in Each Group</title>
          <units>deaths</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events Requiring Withdrawal in Each Group</title>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg injectable subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events Requiring Withdrawal in Each Group</title>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Anakinra</title>
          <description>Anakinra 100 mg injectable subcutaneously daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>0.67 ml of NaCl 0.9% solution</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>New onset heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Recurrent myocardial infarction or repeat percutaneous coronary intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Left ventricular thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cardiac rupture</sub_title>
                <description>Cardiac rupture</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Serious infection</sub_title>
                <description>requiring or prolonging hospital admission, or requiring intravenous antibiotics</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding (not serious)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (not serious)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Antonio Abbate</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-0513</phone>
      <email>aabbate@mcvh-vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

